Implantable cardioverter defibrillator in maintenance hemodialysis patients with ventricular tachyarrhythmias: a single-center experience.

Patients with hemodialysis (HD) are at risk of death due to cardiac arrhythmias, worsening congestive heart failure (CHF), and noncardiac causes. This study reviews our experience with the use of implantable cardioverter defibrillators (ICDs) in patients with ventricular tachycardia who are under maintenance HD. We retrospectively reviewed 71 consecutive patients who underwent an ICD implantation in our hospital. There were 11 patients under maintenance HD and 60 patients without HD. The group of patients with HD (HD group) was compared with the patients without HD (control group). The mean follow-up period was 30+/-9 vs. 39+/-4 months in the HD group vs. the control group, respectively. Among these patients, 6 in the HD group and 26 in the control group received appropriate ICD therapies. There was no difference in appropriate ICD therapy, time to the first therapy, and electrical storm between the 2 groups. In the HD group, 1 patient underwent surgical removal of the ICD system due to infective endocarditis. There were 5 deaths in the HD group (4 from CHF) and 8 deaths in the control group (4 from CHF). There were no sudden cardiac deaths or arrhythmic deaths in both groups of patients during the follow-up period. However, the overall death rate was significantly higher in the HD group (P<0.01). In HD patients, ICD therapy prevented arrhythmic death, but their rate of nonarrhythmic adverse outcomes was high. This risk-benefit association should be considered before implantation of the device.

Right atrial abnormalities in a patient with arrhythmogenic right ventricular cardiomyopathy without ventricular tachycardia.

We describe a 59-year-old woman with sick sinus syndrome (SSS) and arrhythmogenic right ventricular cardiomyopathy (ARVC). Diagnosis of SSS was made because she had frequent episodes of sinus arrest with prolonged ventricular asystole. Cardiac images showed a dilated right atrium (RA) and a right ventricle (RV). Electroanatomical mapping of the RA showed extensive scarring with no recordable electrical potentials. Although she had frequent premature ventricular contractions, neither spontaneous ventricular tachycardia (VT) nor induced VT was observed. Microscopic examination of the RV indicated fibrofatty myocardium. Atrial arrhythmias associated with SSS may be the cause of symptoms in some cases of ARVC.

Delayed pericarditis associated with an implantable cardioverter defibrillator implantation using an active-fixation atrial lead.

A 57-year-old man with nonischemic dilated cardiomyopathy and ventricular tachycardia underwent routine dual chamber implantable cardioverter defibrillator (ICD) implantation. An active-fixation atrial lead was positioned at the lateral wall of the right atrium. He subsequently developed chronic severe pericarditis. Histopathological findings of the pericardium showed mechanical stimulus localized pericarditis. This case demonstrates that contact of the screw of the active-fixation atrial lead with the pericardium may be a possible mechanism for pericarditis after pacemaker/ICD implantation.

Significance and utility of plasma brain natriuretic peptide concentrations in patients with idiopathic ventricular arrhythmias.

BACKGROUND: Secretion of B-type natriuretic peptide (BNP) appears to be regulated mainly by wall tension, and an increase in the plasma BNP concentration is considered to reflect ventricular structural and functional abnormalities. The aim of this study was to clarify the significance and utility of the measurement of the plasma BNP in the setting of idiopathic ventricular arrhythmias (I-VT/PVCs). METHODS: This study included 135 patients with symptomatic, monomorphic I-VT/PVCs (73 women; 53 +/- 17 years; 50 ventricular tachycardias [VTs], 85 premature ventricular contractions) who underwent radiofrequency catheter ablation. None had structural heart disease or renal dysfunction. RESULTS: The plasma BNP concentration exceeded the normal range (>18.4 pg/mL; high BNP concentration) in 79 patients (56%). The high BNP concentration was found more often in I-VT/PVCs originating from the left ventricle (LV; 74%) than the right ventricle (RV; 49%; P < 0.01). The plasma BNP concentration correlated with the age (P = 0.0001) and frequency of premature ventricular contractions (P < 0.0001), and left-sided I-VT/PVCs and the presence of controlled hypertension were independent predictors of a high BNP concentration (both P < 0.05). In patients with a successful ablation and high BNP concentration before the ablation, the BNP concentration decreased to the normal range in 61% of patients after ablation. In patients with a failed ablation, the BNP concentration did not decrease to the normal range after ablation in any of the patients (P < 0.0005). CONCLUSIONS: The plasma BNP concentration was elevated in about 60% of the patients with symptomatic I-VT/PVCs. Normalization of the high BNP concentration after ablation may indicate a successful ablation.

[Comparison of clinical and angiographic outcomes between S670 and NIR stents].

OBJECTIVES: This study evaluated the long-term outcomes of successfully implanted S670 and NIR stents. METHODS: Stents were successfully implanted in 143 patients (148 lesions) aged 65 +/- 9 years from January 1999 to April 2001. Sixty-eight lesions were treated with S670 stents and 80 with NIR stents. Quantitative coronary angiography was performed before, immediately after and 6 months after implantation. An angiographic classification of in-stent restenosis was developed according to the geographic distribution of intimal hyperplasia in reference to the implanted stent. Furthermore, the relationships between stent diameter and length and restenosis rate were estimated. RESULTS: Type B2/C lesions were significantly more common in patients with S 670 (77.3%) stents compared with NIR (43.6%). Stent length was longer and diameter was smaller in patients with S 670 stents compared with those with NIR stents. Acute-gain was similar in the two groups, but late-loss was significantly greater in patients with S 670 stents compared with those with NIR stents. Restenosis rate and target lesion revascularization rate were similar in the two groups. The diffuse type of restenosis lesion was frequently found in S 670 stents. The stent diameter, but not stent length, influenced the restenosis rate in S 670 stents. Both stent length and diameter influenced the restenosis rate in NIR stents. CONCLUSIONS: Late-loss was larger and in-stent restenosis of diffuse type was significantly greater in S 670 stents compared with NIR stents. However, stent length was significantly longer and type B2/C lesions were significantly greater in S 670 stents compared with NIR stents. There was no difference in restenosis rate and target lesion revascularization rate. In addition, restenosis rate was not influenced by stent length in S 670 stents, so S 670 stents may be useful for complex lesions.